Abstract:Zidovudine is a synthetic nucleoside analogue, specifically a nucleoside reverse transcriptase inhibitor (NRTI), that inhibits the replication of retroviruses, including HIV. Study Objective: This study objective was to determine the bioequivalence of Zidovudine 100 mg capsules produced by PT Kimia Farma Tbk compared to Retrovir 100 mg capsules produced by GlaxoSmithKline Pharmaceuticals S.A, in healthy subjects Methods: The study was conducted in a randomized, single-dose, open-label, two-way crossover design (2 treatments, 2 periods, and 2 sequences) under fasting state with 7 (seven) days washed-out period between each period. The number of subjects who participated and completed the study were 31 of 32 adult male and female. One subject dropped out from 2nd period because of personal reason. The subjects received an explanation of the study and signed informed consent. Subjects fasted for a minimum of 8 hours before receiving the test drug and reference drug. Blood samples were collected 15 times at the following time points: 0 hours (before drug administration), 0.16, 0.33, 0.50, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours after drug administration. Plasma concentrations of the drug were determined by LC-MS/MS method. The pharmacokinetic parameters calculated in this study are AUC0-t, AUC0-inf, Cmax, tmax, and t1⁄2, while the statistical interval proposed was 80.00 - 125.00% for AUC0-t and Cmax with 90% Confidence Interval (CI) with α = 5.00%. Results: The main pharmacokinetic parameters of the test drug Zidovudine (BN: G2 1346 J) compared to reference drug, Retrovir (BN: JN8K) were calculated based on geometric mean ratio and 90% confidence interval (CI). The results for AUC0-t and Cmax were 101.65% (96.77- 106.83%) and 95.63% (84.09-108.76%) respectively, with intra-subject variability (%CV) for AUC0-t and Cmax were 11.49% and 30.47%. Hence, the number of 31 subjects has adequate number for required power of study. Conclusion: Based on the AUC0-t and Cmax values, Zidovudine 100 mg Capsules Produced by PT. Kimia Farma Tbk is bioequivalent to Retrovir 100 mg Capsules Produced by GlaxoSmithKline Pharmaceuticals S.A.

Studies on Bioequivalence of Indinavir Capsule in Healthy Volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Studies on the Bioequivalence of Lorazepam Tablet in Healthy Volunteers

Pharmacokinetics and relative bioavailability of domestic vs imported cefpodoxime proxetil tablets in human body

Pharmacokinetics and Bioequivalence Study of Two Formulations of Favipiravir 200 mg Film-Coated Tablet in Healthy Indonesian Volunteers

Study on Bioequivalence of Glucosamine Indometacin Enteric-coated Tablets in Healthy Volunteers

Bioequivalence study of fluoxetine capsules in healthy volunteers

Evaluation of the bioequivalence and pharmacokinetics of two formulations of secnidazole after single oral administration in healthy volunteers

Studies on Bioequivalence of Domestic Diisopropylamine Dichloroacetate Tablet and Capsule in Healthy Volunteers

Bioequivalence of Two Cilnidipine Formulations in Healthy Chinese Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioequivalence of erythromycin enteric-coated capsules in healthy volunteers

Bioeguivalent Study of Two Fluconazole Capsules in Human Plasma

Bioequivalent Study of Citalopram Tablets

Bioequivalence of Two Nizatidine Capsules in Healthy Volunteers

Bioequivalence Study of Zidovudine 100 Mg Capsule with TwoWay Crossover Design

Bioequivalence of domestic and imported ceftibuten tablets in healthy volunteers

Bioequivalence of domestic and imported bisoproloi tablets

Bioequivalence Study of Domestic Made Cefpodoxime Proxetil Capsules in Healthy Volunteers

Bioequivalence of Valaciclovir Hydrochlordide Tablets in Healthy Volunteers